Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18, 2025 - JSPR

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [3][5]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [5]. - The company’s public statements were claimed to be materially false and misleading due to these failures [5]. Group 3: Stock Price Impact - Following a press release on July 7, 2025, which revealed issues with a drug product lot and subsequent halting of studies, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share [6].